« Back to News

Coldstream To Make CYT-6091 for Ph II

coldstream_logoColdstream Laboratories, Inc. will manufacture CytImmune‘s CYT-6091 for injection in preparation for Phase II clinical trials. CYT-6091 is part of CytImmune’s Aurimune platform. Specifically, Coldstream will perform scale-up and optimization of the manufacturing and lyophilization process to enable the manufacture of clinical trial materials.

CYT-6091 is comprised of gold nanoparticles bound with an immune-avoiding component (PEG-Thiol) and tumor necrosis factor alpha (TNF) which has been successfully tested at the National Cancer Institute, Bethesda, MD, in a Phase I clinical trial in advanced-stage cancer patients. As seen in that study, the gold nanoparticles were observed to accumulate in tumor tissues while leaving healthy tissue unaffected. The Aurimune platform provides a significantly enhanced safety profile for TNF when formulated as CYT-6091 compared to systemically administered TNF.

The Phase II trials, to be conducted in New York City at Montefiore Einstein Center for Cancer Care will scale production tenfold from Phase I manufacturing. The study will be designed to test how well CYT-6091 benefits lung cancer patients.

Dr. Lawrence Tamarkin, CytImmune’s CEO said, “We have seen proven success of CYT-6091 in Phase I clinical trials. We are looking forward to partnering with Coldstream in preparation for Phase II trials in an effort to move cancer care forward.”

Coldstream’s President & CEO, Eric W. Smart, added, “We are extremely pleased that CytImmune has chosen Coldstream as their CMO. We are confident that the encouraging results from CYT-6091 trials paired with Coldstream’s parenteral manufacturing expertise will lead to a successful relationship and improve treatments available to cancer patients.”

Coldstream Laboratories is a Founding Member of the Pharma & Biopharma Outsourcing Association. Visit our Benefits page to learn more about the PBOA.